Fmoc-L-Lys[tBuO-C20-L-Glu(AEEA-AEEA)-OtBu]-OH
2915356-76-0
99%
Shanghai,Guangzhou
Congen
1kg/bag, 1g/bag, 50g/bag
2025-01-31
Salcaprozate Sodium,2-(2-(2-aminoethoxy)ethoxy)acetic acid(AEEA),[2-(2-{2-[2-(2-aminoethoxy)ethoxy]acetylamino}ethoxy)ethoxy]acetic acid (AEEA-AEEA),Fmoc-AEEA-OH,Fmoc-AEEA-AEEA-OH,Boc-L-His(Trt)-Aib-OH
-
Product Description
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
Tirzepatide Intermediate, Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH CAS 2915356-76-0
CAS No.:2915356-76-0
Categories:
Research-
Class:
Dual agonist — GIPR, GLP-1R
Status:FDA-approved (Mounjaro / Zepbound)
Mechanism:Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.
EC50 (Human GLP1R):0.934 nM
EC50 (Human GIPR):0.0224 nM
Source:Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI
Clinical Development:NCT03954834; NCT03987919; NCT03882970; NCT03730662; NCT04039503
FDA:Mounjaro, Zepbound (approved 2022-05-13)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Salcaprozate Sodium,2-(2-(2-aminoethoxy)ethoxy)acetic acid(AEEA),[2-(2-{2-[2-(2-aminoethoxy)ethoxy]acetylamino}ethoxy)ethoxy]acetic acid (AEEA-AEEA),Fmoc-AEEA-OH,Fmoc-AEEA-AEEA-OH,Boc-L-His(Trt)-Aib-OH
-
Location:
Room 206, Building G12, South China Advanced Materials Innovation Park, No. 31 Kefeng Road, Huangpu Dist. Guangzhou,China
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
40
-
Total Annual Revenue:
$50 million-$100 million
-
Total Employees:
51-100
-
Year of Establishment:
2013
-
Certifications:
certificate of patent
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product